Docoh
Loading...

GNFT Genfit

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.

GNFT stock data

(
)

Calendar

23 Apr 21
24 Jan 22
31 Dec 22
Quarter (USD)
Dec 20 Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Genfit earnings reports.

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

1.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 10 10
Opened positions 1 3 -66.7%
Closed positions 1 4 -75.0%
Increased positions 3 2 +50.0%
Reduced positions 4 2 +100.0%
13F shares
Current Prev Q Change
Total value 2.25M 2.43M -7.5%
Total shares 607.8K 634.02K -4.1%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Millennium Management 318.45K $1.18M -6.2%
DAFNA Capital Management 188.55K $698K 0.0%
MS Morgan Stanley 54.34K $201K +3.8%
Citadel Advisors 23.63K $87K -32.4%
HRT Financial 16.77K $62K +9.9%
UBS UBS Group AG - Registered Shares 3.65K $14K +46.9%
Optiver Holding B.V. 1.83K $7K NEW
Banque Cantonale Vaudoise 500 $2K 0.0%
Tower Research Capital 85 $0 -70.2%
BCS Barclays 2 $0 -89.5%
Largest transactions
Shares Bought/sold Change
Millennium Management 318.45K -21.08K -6.2%
Citadel Advisors 23.63K -11.33K -32.4%
MS Morgan Stanley 54.34K +2K +3.8%
Optiver Holding B.V. 1.83K +1.83K NEW
HRT Financial 16.77K +1.5K +9.9%
UBS UBS Group AG - Registered Shares 3.65K +1.17K +46.9%
Tower Research Capital 85 -200 -70.2%
Advisory Services Network 0 -100 EXIT
BCS Barclays 2 -17 -89.5%
Proequities 0 0
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg

Proxies

No filings